QNCX Reports Phase 2a LAM-001 Trial Success, +67.4m 6MWD, -33.9% PVR in PH-ILD Patients, Plans Phase 2b Mid-2026
Quince Therapeutics, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $1.15
+18% in 7d after detection
Post-detection moves
1h
—
1d
+7.6%
3d
+7.6%
7d
+18%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS